Pharmaceutical

TRACON Pharmaceuticals (NASDAQ:TCON) is a clinical stage biopharmaceutical company that develops and commercializes novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases. The company reported that it has updated positive results from a Phase 1b clinical trial combining TRC105 with Inlyta® (axitinib) in patients with advanced or metastatic renal cell carcinoma (RCC).

TRACON Pharmaceuticals (NASDAQ:TCON) is a clinical stage biopharmaceutical company that develops and commercializes novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases. The company reported that it has updated positive results from a Phase 1b clinical trial combining TRC105 with Inlyta® (axitinib) in patients with advanced or metastatic renal cell carcinoma (RCC).

According to the press release:

The open-label dose escalation and expansion Phase 1b study enrolled patients who had received at least one prior line of therapy with a VEGF receptor tyrosine kinase inhibitor (VEGFR TKI).  The median number of prior therapies was three (range of one to six). All patients in the trial received a combination of TRC105 and Inlyta.

Click here to read the full press release.

 

MARKETS

Markets
TSX20179.81+187.93
TSXV680.49+7.47
DOW33761.05+424.38
S&P 5004280.15+72.88
NASD13047.19+267.27
ASX7032.50-38.50

COMMODITIES

Commodities
Gold1801.89+0.36
Silver20.82+0.02
Copper3.68-0.03
Palladium2224.19+14.20
Platinum965.47+2.48
Oil91.88-2.46
Heating Oil3.51+0.03
Natural Gas8.78-0.09

DOWNLOAD FREE REPORTS

×